Moderna Soars 90%, Merck Jumps on Cancer Vaccine Trial Win

Moderna and Merck have seen significant gains in their stock prices. Moderna's shares have soared by 90%, while Merck has jumped after a successful cancer vaccine trial.

The gains come as investors react positively to the news that Merck's KEYTRUDA treatment has shown promising results in treating certain types of lung and skin cancers.

According to information from Nasdaq, Moderna's stock price closed at $154.93 per share on [no specific date mentioned], while Merck's price was up 4% to $83.44 per share.